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Bacterial infections, such as tuberculosis, have been identified as a world-wide problem 
leading to the deaths of millions of people each year. The importance of developing new 
drugs to fight infectious disease caused by these pathogenic organisms is underscored by 
the emergence of several bacterial strains that are resistant to all currently available 
antibiotics.1-4 Antibiotics, such as β-lactams, succeed by targeting vital cellular functions 
either killing the organism or hindering their multiplication. However, through evolution, 
bacteria will most likely develop resistance to these drugs rendering them useless. Targeting 
new bacterial-specific pathways is a valid approach to combating this problem. 
The meso-diaminopimelate (mDAP)/lysine biosynthetic pathway offers several potential 
anti-bacterial targets that have yet to be explored.5-7 Since both products of this pathway, 
mDAP and lysine, are essential components for the synthesis of the peptidoglycan cell wall 
in Gram-negative and some Gram-positive bacteria, inhibitors of enzymes within this 
pathway may provide a new class of antibiotics.3 The fact that there are no similar pathways 
in mammals suggests that inhibitors of enzymes in the mDAP/lysine pathway will provide 
selective toxicity against bacteria and have little or no effect on humans. 
One of the enzymes in this pathway,8 the dapE-encoded N-succinyl-L,L-diaminopimelic acid 
desuccinylase (DapE), catalyzes the hydrolysis of N-succinyl-L,L-diaminopimelate to L,L-
diaminopimelate and succinate.9 It has been shown that deletion of the gene encoding DapE 
is lethal to Helicobacter pylori and Mycobacterium smegmatis.10,11 Therefore, DapEs are 
essential for cell growth and proliferation making them potential molecular targets for a new 
class of antibiotics. 
Rational design of inhibitors for DapE relies on an understanding of the active site structure 
and mechanism. DapE is known to be a metallohydrolase utilizing Zn at its active site, but 
no crystallographic information is available. We have used Zn K-edge Extended X-ray 
Absorption Fine Structure (EXAFS) data, of DapE from Haemophilus influenzae in the 
presence of one or two equivalents of Zn(II) (i.e. [Zn_(DapE)] and [ZnZn(DapE)]), to 
provide structural information about the active site.12 The Fourier transforms of the Zn 
EXAFS are dominated by a peak at ca. 2.0 Å, which can be fit for both [Zn_(DapE)] and 
[ZnZn(DapE)] assuming ca. 5 (N,O) scatterers at 1.96 and 1.98 Å, respectively.  A second-
shell feature at ca. 3.34 Å appears only in the [ZnZn(DapE)] FT, demonstrating that DapE 
contains a dinuclear Zn(II) active site. 
In addition, Zn EXAFS data for DapE incubated with two competitive inhibitors, 2-
carboxyethylphosphonic acid (CEPA) and 5-mercaptopentanoic acid, establish the binding 
modes of phosphonate- and thiolate-containing inhibitors. The structural data obtained for 
CEPA bound to [ZnZn(DapE)] also provides an initial understanding of the transition state 
for the hydrolysis reaction catalyzed by DapE. Since most pharmaceuticals target the 
transition state of enzymatic reactions, the structural aspects of [ZnZn(DapE)]-CEPA are 
particularly important for the rational design of new potent inhibitors of DapE enzymes. 
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